Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer to Canada

Patient Enrollment in the United States Ongoing

SAN DIEGO, March 8, 2016 /CNW/ — Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced that its randomized, controlled Phase 2/3 clinical trial, called Toca 5, has expanded internationally and is now…